BACKGROUND: Anaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with a median survival of 3-5 months. The BRAF oncogene is mutated to its active form in up to 24% of ATC cases. Sorafenib is a tyrosine kinase inhibitor that acts on the RAF-1 serine/threonine kinase. In preclinical mouse models, sorafenib inhibits the growth of ATC xenografts and improves survival. No study of sorafenib in ATC has been conducted. We conducted a multi-institutional phase II trial of sorafenib in patients with ATC who had failed up to two previous therapies. METHODS: The primary endpoint of the trial was the Response Evaluation Criteria In Solid Tumors (RECIST)-defined imaging response rate. Twenty patients with ATC were treated with sorafenib 400 mg twice daily. RESULTS: Two of the 20 patients had a partial response (10%) and an additional 5 of 20 (25%) had stable disease. The duration of response in the two responders was 10 and 27 months, respectively. For the patients with stable disease, the median duration was 4 months (range 3-11 months). The overall median progression-free survival was 1.9 months with a median and a 1-year survival of 3.9 months and 20%, respectively. Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash. CONCLUSION: Sorafenib has activity in ATC, but at a low frequency and similar to our previous experience with fosbretabulin. One patient with a response had previously progressed on fosbretabulin. Toxicities were both predictable and manageable.
BACKGROUND:Anaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with a median survival of 3-5 months. The BRAF oncogene is mutated to its active form in up to 24% of ATC cases. Sorafenib is a tyrosine kinase inhibitor that acts on the RAF-1 serine/threonine kinase. In preclinical mouse models, sorafenib inhibits the growth of ATC xenografts and improves survival. No study of sorafenib in ATC has been conducted. We conducted a multi-institutional phase II trial of sorafenib in patients with ATC who had failed up to two previous therapies. METHODS: The primary endpoint of the trial was the Response Evaluation Criteria In Solid Tumors (RECIST)-defined imaging response rate. Twenty patients with ATC were treated with sorafenib 400 mg twice daily. RESULTS: Two of the 20 patients had a partial response (10%) and an additional 5 of 20 (25%) had stable disease. The duration of response in the two responders was 10 and 27 months, respectively. For the patients with stable disease, the median duration was 4 months (range 3-11 months). The overall median progression-free survival was 1.9 months with a median and a 1-year survival of 3.9 months and 20%, respectively. Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash. CONCLUSION:Sorafenib has activity in ATC, but at a low frequency and similar to our previous experience with fosbretabulin. One patient with a response had previously progressed on fosbretabulin. Toxicities were both predictable and manageable.
Authors: Giuliana Salvatore; Valentina De Falco; Paolo Salerno; Tito Claudio Nappi; Stefano Pepe; Giancarlo Troncone; Francesca Carlomagno; Rosa Marina Melillo; Scott M Wilhelm; Massimo Santoro Journal: Clin Cancer Res Date: 2006-03-01 Impact factor: 12.531
Authors: Sam M Wiseman; Thom R Loree; Nestor R Rigual; Wesley L Hicks; Wade G Douglas; Garth R Anderson; Daniel L Stoler Journal: Head Neck Date: 2003-08 Impact factor: 3.147
Authors: Bin Ouyang; Jeffrey A Knauf; Eric P Smith; Lei Zhang; Tim Ramsey; Naeem Yusuff; David Batt; James A Fagin Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen Journal: J Clin Endocrinol Metab Date: 2008-08-19 Impact factor: 5.958
Authors: Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2015-09 Impact factor: 11.908
Authors: Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen Journal: Oncologist Date: 2014-09-26
Authors: Anna Anschlag; Brandon H Greene; Lorianna KÖnneker; Markus Luster; James Nagarajah; Sabine WÄchter; Annette Wunderlich; Andreas Pfestroff Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer Journal: Eur Arch Otorhinolaryngol Date: 2020-02-14 Impact factor: 2.503